To ATCC Valued Customers,

ATCC stands ready to support our customers’ needs during the coronavirus pandemic. Our first job is to listen to and observe what our customers need, and meet those needs with quality products and services. While we are not currently experiencing delays due to this pandemic, we expect that we could see them as the situation evolves. If you experience any issues, please contact ATCC Customer Service at For Technical questions please contact Thank you for your understanding, patience and flexibility as ATCC does everything it can to help reduce the impact of the coronavirus pandemic to our valued customers.

HCC1395 (ATCC® CRL-2324)

Organism: Homo sapiens, human  /  Cell Type: Epithelial, lymphoblast  /  Tissue: mammary gland; breast/duct  /  Disease: TNM stage I, grade 3, primary ductal carcinoma

Permits and Restrictions

View Permits View Restrictions

Organism Homo sapiens, human
Tissue mammary gland; breast/duct
Cell Type Epithelial, lymphoblast
Product Format frozen
Morphology epithelial
Culture Properties adherent
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease TNM stage I, grade 3, primary ductal carcinoma
Age 43 years adult
Gender female
Ethnicity Caucasian, White
Storage Conditions liquid nitrogen vapor phase
Karyotype polyploid
This cell line was initiated on 12/14/94 from a patient with a family history of cancer (patient's mother had breast cancer). The cell line took 14 months to establish.
Clinical Data
43 years
Caucasian, White
An EBV transformed lymphoblastoid cell line (HCC1395BL) from the same patient is available as ATCC CRL-2325.
Receptor Expression
estrogen receptor, negative according to depositor
progesterone receptor, negative
Oncogene her2/neu -, p53 +
Genes Expressed
Epithelial glycoprotein 2 (EGP2),cytokeratin 19
Cellular Products
Epithelial glycoprotein 2 (EGP2)
cytokeratin 19
The tumor was classified as TNM stage I, grade 3, invasive ductal carcinoma with 0 out of 34 lymph node metastasis.

The cells are poorly differentiated and vacuolated. 

The cells are negative for expression of Her2-neu but positive for expression of p53.

HCC1395 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19.

The cells are negative for expression of estrogen receptors (ER -) according to depositor and negative for expression of progesterone receptors (PR -).

An EBV transformed lymphoblastoid cell line (HCC1395BL) from the same patient is available as ATCC CRL-2325.

Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
Subculturing Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.

  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin-0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C

Subculture Ratio: 1:2
Medium Renewal: Every 2 to 3 days.
Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994.

Freeze medium: Complete growth medium 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Temperature: 37°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
STR Profile
Amelogenin: X
CSF1PO: 11
D13S317: 9
D16S539: 11
D5S818: 11
D7S820: 10,12
TH01: 9.3
TPOX: 11
vWA: 15
Name of Depositor AF Gazdar, AK Virmani
Year of Origin December 14, 1994

Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation

The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email, or Fax: (214) 951-0935.


Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771